Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 5/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102677 | 0.89 | VSIR (0.38) | PSMB5AKT1AKT2 | |
| SCHEMBL13005210 | 0.86 | AKT1 (0.39) | PSMB5PDE10AAKT1AKT2 | |
| SCHEMBL10102678 | 0.84 | AKT1 (0.37) | PSMB5PDE10AKCNH2AKT1AKT2 | |
| SCHEMBL10102668 | 0.81 | PSMB5 (0.44) | PSMB5PDE10A | |
| SCHEMBL13005203 | 0.78 | AKT1 (0.36) | PSMB5PDE10ADHFRAKT1AKT2 | |
| SCHEMBL3386183 | 0.75 | PIK3CG (0.40) | LMNA | |
| SCHEMBL10102655 | 0.74 | PDE4B (0.37) | — | |
| SCHEMBL3383001 | 0.74 | DHODH (0.45) | KCNH2DHFRTYMS | |
| SCHEMBL10102645 | 0.72 | CNR2 (0.38) | KCNH2 | |
| SCHEMBL27660917 | 0.72 | TLR8 (0.63) | PSMB5PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | MERCK PATENT GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | MERCK PATENT GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | KIF5A, KIF5C, KIF5B | PSMB5 228/4885PDE10A 4376/4885KCNH2 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.